Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Ultra-Rare Disease Studying Subjects Aged 3 Years and Younger

A Natural History Rare Disease Case Study

Read the Case Study

About the Case Study

Pharm-Olam was contracted to execute a multicenter, pre-Phase I non-interventional study centered on young children, aged 3 years and younger, who have an Ultra-Rare Disease. There was no investigational product to evaluate. It was a natural history study designed to clinically assess disease progression in patients and the burden of the condition as it relates to caregivers. This natural history study has acted as a critical dataset for driving the future of their development program and future clinical studies.

Program Overview: Pre-Phase 1

Indication: Multicenter, Non-interventional Natural History Study to Observe Young Pediatric Subjects with an Ultra Rare Disease (1 in 50,000 newborns)

Sites & Locations: 8 sites, 5 countries

Services Provided:

  • Project Management
  • Clinical Operations & Trial Management
  • Pharmacovigilance
  • Quality Assurance

How can we help you create a healthier world?

Talk to one of our experts today.

Please choose one.

Contact Us